RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:101010

Autosomal spastic paraplegia type 30

high confidenceDisorder

Also known as: SPG30

Publications

167

72.3th percentile

Trials

0

Interventional, condition-specific

Researchers

1,915

Distinct authors in sample

Gene link

KIF1A

Strong

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare, pure or complex form of spastic paraplegia characterized by either a pure spastic paraplegia , usually presenting in the first or second decade of life, with spastic lower extremities, unsteady spastic gait, hyperreflexia and extensor plantar responses, or as a complicated with the additional manifestations of distal wasting, saccadic ocular movements, mild cerebellar and mild, distal, axonal .

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (5)

KIF1A hereditary spastic paraplegia · autosomal spastic paraplegia type 30 · hereditary spastic paraplegia caused by mutation in KIF1A · hereditary spastic paraplegia type 30 · spastic paraplegia 30, autosomal dominant

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedPresent

    Strong — KIF1A

  2. LiteraturePresent

    167 matched papers (138 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 102 for broader category paraplegia

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (KIF1A).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

167

167 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

167 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

138 in the last 10 years · high confidence · 72.3th percentile (publications denominator)

Phrase hits: 166 · MeSH hits: 1

Open Europe PMC search

Who's working on it?

1,915

Distinct author names in 167 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Berindan-Neagoe I12 papers · 2023

    Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

    Papers in Europe PMC
  2. 02
    Stevanin G11 papers · 2021

    Sorbonne Université UMR S 1127, Paris, France.

    Papers in Europe PMC
  3. 03
    Burz C8 papers · 2023

    Department of Immunology and Allergology, Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

    Papers in Europe PMC
  4. 04
    Chelaru V8 papers · 2023

    Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

    Papers in Europe PMC
  5. 05
    Pralea I8 papers · 2023

    Research Center for Advanced Medicine MedFUTURE, Cluj-Napoca, Romania

    Papers in Europe PMC
  6. 06
    Ţigu A8 papers · 2023

    Research Center for Advanced Medicine MedFUTURE, Cluj-Napoca, Romania

    Papers in Europe PMC
  7. 07
    Toma V8 papers · 2023

    Research Center for Advanced Medicine MEDFUTURE, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Romania

    Papers in Europe PMC
  8. 08
    Tomuleasa C8 papers · 2023

    Research Center for Advanced Medicine MEDFUTURE, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Romania

    Papers in Europe PMC
  9. 09
    Vlase L8 papers · 2023

    Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

    Papers in Europe PMC
  10. 10
    Grama A7 papers · 2023

    Department of 2 Pediatric Clinic, Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 102 trials are registered for paraplegia, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

102 interventional trials matched paraplegia, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: paraplegia

102

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Autosomal spastic paraplegia type 30" OR "SPG30" OR "KIF1A hereditary spastic paraplegia" OR "hereditary spastic paraplegia caused by mutation in KIF1A" OR "hereditary spastic paraplegia type 30" OR "spastic paraplegia 30, autosomal dominant"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Spastic Paraplegia 30, Autosomal Recessive

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Autosomal spastic paraplegia type 30" OR "SPG30" OR "KIF1A hereditary spastic paraplegia" OR "hereditary spastic paraplegia caused by mutation in KIF1A" OR "hereditary spastic paraplegia type 30" OR "spastic paraplegia 30, autosomal dominant" OR "Spastic Paraplegia 30, Autosomal Recessive" OR "KIF1A"

Recall-expansion terms: KIF1A

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"paraplegia"

Query health: ok — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T07:12:30.729Z